Equities research analysts expect OvaScience Inc. (NASDAQ:OVAS) to post ($0.29) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for OvaScience’s earnings, with estimates ranging from ($0.32) to ($0.28). OvaScience posted earnings per share of ($0.64) in the same quarter last year, which would indicate a positive year over year growth rate of 54.7%. The business is scheduled to issue its next quarterly earnings report on Thursday, March 1st.
On average, analysts expect that OvaScience will report full year earnings of ($1.48) per share for the current year, with EPS estimates ranging from ($1.51) to ($1.47). For the next financial year, analysts forecast that the company will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.33) to ($0.92). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for OvaScience.
A number of research analysts have weighed in on OVAS shares. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Wednesday, October 4th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of OvaScience in a research note on Monday, November 6th. Finally, Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of OvaScience in a research note on Thursday, August 3rd.
OvaScience (NASDAQ OVAS) opened at $1.34 on Wednesday. OvaScience has a 52 week low of $1.25 and a 52 week high of $4.20.
Several institutional investors have recently made changes to their positions in OVAS. GMT Capital Corp acquired a new stake in shares of OvaScience during the third quarter valued at about $1,138,000. Legal & General Group Plc lifted its holdings in OvaScience by 4,654.1% in the second quarter. Legal & General Group Plc now owns 458,822 shares of the biotechnology company’s stock worth $713,000 after acquiring an additional 449,171 shares during the last quarter. Broadfin Capital LLC bought a new stake in shares of OvaScience during the second quarter valued at approximately $429,000. KCG Holdings Inc. bought a new stake in shares of OvaScience during the first quarter valued at approximately $375,000. Finally, LMR Partners LLP bought a new stake in shares of OvaScience during the second quarter valued at approximately $145,000. Institutional investors own 56.06% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Analysts Anticipate OvaScience Inc. (OVAS) to Post -$0.29 EPS” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/15/analysts-anticipate-ovascience-inc-ovas-to-post-0-29-eps.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.